Canada Drugs Direct

Visiting from Canada?

Want to save up to 80% on your medications? Signup below to be notified if we open a Canadian Online Pharmacy.

I agree to receive email updates from Canada Drugs Direct

Looking for CanadaDrugsDirect.net? Call us toll free 1-800-500-2897

Olumiant (Baricitinib)

Prescription medicineOnly Available By Prescription
Sezzle

Top brand choice

Strength Pack Size Qty
Strength
2mg
Pack Size
Qty
Strength
4mg
Pack Size
Qty

You'll have option to make 4 interest-free payments by credit card once your order is confirmed using

Top Generic choice

Strength Pack Size Qty
Strength
2mg
Pack Size
Qty
Strength
4mg
Pack Size
Qty

You'll have option to make 4 interest-free payments by credit card once your order is confirmed using

What if I find a lower price with another pharmacy?

We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!

Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.

To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.

Terms & Conditions of Program

  • Guaranteed lowest price is only valid at the time of sale.
  • We will only match the current advertised price.
  • Products must be identical and in stock at the time of placing an order with a licensed mail order pharmacy. The must be a member of CIPA (Canadian International Pharmacy Association).
  • Products must be authentic in brand and size (same manufacturer, same country of manufacture, same pack size, same strength and same quantity).
  • Products must be new. We cannot match the price of any used, short expiry or expired product.
  • Price match can only be issued over the phone with our customer service team
What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Description

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor used to treat moderate to severe rheumatoid arthritis in adults who received one or more tumor necrosis factor (TNF) blockers that did not respond well or could not be tolerated.

Olumiant is supplied in 1 mg and 2 mg tablets.


Fact Table

Formula

C16H17N7O2S

License

EU EMA, US DailyMed

Bioavailability

79%

Legal status

Rx-Only

Chemical Name

Baricitinib

Elimination half-life

12.5 hours

Dosage (Strength)

2mg, 4mg

Pregnancy

Contraindicated

Brands

Olumiant

Protein binding

50%

PubChem CID

44205240

MedlinePlus

a618033

ChEBI

95341

ATC code

L04AA37

DrugBank

DB11817

KEGG

D10308

Routes of administration

By mouth

Directions

The recommended dose is 2 mg by mouth once daily. Olumiant can be taken with or without food. 

Patients who have kidney problems or take strong Organic Anion Transporter 3 (OAT) inhibitors such as probenecid may be dosed at 1 mg by mouth once daily.

Ingredients

Baricitinib is the active ingredient in each tablet.

Cautions

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS

See full prescribing information for complete boxed warning.

  • Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. 
  • Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. 
  • Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. 
  • Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. 
  • Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. 

Tell your doctor if you have an active infection or an infection that won't go away or keeps returning. Tell your doctor if you have tuberculosis or if you have been around someone who has tuberculosis. Olumiant may increase the risk for serious infections and opportunistic infections. Contact your doctor immediately if you experience a cough, fever, diarrhea, stomach pain, shortness of breath, weight loss, blood in your phlegm, fatigue, achy muscles, skin that's painful, red, or warm, sores on your body, burning while urinating, or needing to urinate more often.

The risk of death is increased in patients who are at least 50 years old who have one or more risk factors for cardiovascular disease and take a JAK inhibitor. 

Olumiant may increase your risk for certain cancers such as lung cancer, skin cancer, and lymphomas.

Tell your doctor if you smoke. Tell your doctor if you have heart problems or if you've had a stroke or heart attack. The risk for major cardiovascular events is increased in patients who are at least 50 years old who have one or more risk factors for cardiovascular disease and take a JAK inhibitor. Seek immediate emergency care if you feel discomfort in your chest, pain or discomfort in your arm, back, neck, stomach, or jaw, shortness of breath, cold sweats, dizziness, weakness in one part or on one side of your body, slurred speech, or tightness, pressure, pain, or heaviness in your chest, throat, neck, or jaw. 

Tell your doctor if you have had blood clots. Thrombosis has been reported with the use of Olumiant. Contact your doctor right away if you have pain, swelling, or tenderness in your leg, sudden chest pain, or shortness of breath.

Tell your doctor if you have stomach or intestinal problems. Stomach or intestinal tears may occur with Olumiant treatment. Contact your doctor right away if you develop a fever and stomach pain that persists, and bowel changes.

Tell your doctor if you have low blood counts. Abnormal blood counts may occur with Olumiant.

Live vaccines should not be given to patients receiving Olumiant. 

Talk to your doctor about your allergies. Olumiant may cause hypersensitivity reactions that may be severe.

Let your doctor know if you are pregnant or plan to become pregnant.

Let your doctor know if you are breastfeeding or plan to breastfeed.

Tell your doctor about all the medications that you take, including prescription and over-the-counter medications. Olumiant may interact with certain medications which can cause dangerous effects.

Side Effects

Olumiant can cause side effects. The most common include:

  • Upper respiratory tract infections
  • Shingles
  • Nausea
  • Cold sores

References:

  1. Olumiant (baricitinib). Accessed January 3, 2022. 
  2. Olumiant (baricitinib). Indianapolis, IN: Lilly USA, LLC; 2021.


IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

product-reviews Product Reviews